61 citations,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
23 citations,
April 2010 in “Clinical, cosmetic and investigational dermatology” Bimatoprost ophthalmic solution 0.03% safely and effectively increases eyelash growth when applied to the upper eyelid.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
4 citations,
January 2019 in “Elsevier eBooks” Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.
2 citations,
January 2019 in “Applied clinical research, clinical trials and regulatory affairs” Different countries have regulations to ensure the safety of hair care products, with some recalling hair straighteners due to high formaldehyde.
November 2023 in “Dermatology and Therapy” Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
1 citations,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
October 2020 in “Veterinary Dermatology” New treatments and diagnostic methods for various animal skin conditions showed promising results.
1 citations,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
1 citations,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
36 citations,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
28 citations,
December 2005 in “Journal of cosmetic dermatology” Apple procyanidin applied to the scalp may help grow hair without side effects.
13 citations,
January 2021 in “RSC chemical biology” Wnt activation shows promise for regenerative medicine but requires selective targeting to minimize risks like cancer.
March 2008 in “Aging health” Docetaxel is safe and works well for older people with cancer, with manageable side effects.
45 citations,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
8 citations,
May 2010 in “Dermatologic clinics” New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.
165 citations,
December 2002 in “Molecular and Cellular Endocrinology” Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
1 citations,
January 2015 in “Side effects of drugs annual” The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.
213 citations,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
113 citations,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
15 citations,
May 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.
8 citations,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
121 citations,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.